RxDoctor Payments Data

Cameron Wolfe, MD

Infectious Disease · Durham, NCNPI 1396910543

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $76,454 of the $111,672 with a category attached, or 68.5%. 17 manufacturers reported payments, led by CSL Behring at 39.0% of the total. 2025 is the largest year on record at $46,576, 5.7 times the $8,167 reported in 2019. Among infectious disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$111,672in general payments, 2019–2025

Across 74 payments — averaging $1509.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$44K
  • Merck$30K
  • Janssen Research & Development, LLC$12K
  • Paratek Pharmaceuticals, Inc.$5K
  • Gilead$4K
  • Regeneron$3K
  • plus $14K from 11 others
$1,113,287in research payments, 2019–2025

Across 45 payments — averaging $24,740 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$518K
  • Modernatx, Inc.$456K
  • Astrazeneca UK Limited$90K
  • Pfizer$33K
  • Amgen$13K
  • Adamis Pharmaceuticals Corporation$3K
  • plus $905 from 2 others

What the payments were for

  • Consulting fees$76,45468%
  • Speaking & faculty fees$24,57122%
  • Travel & lodging$8,0207%
  • Food & beverage$2,5902%
  • Education$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,672 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,318
Medicare patients
105
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala121$513,054
TriumeqAbacavir/Dolutegravir/Lamivudi106$400,875
DovatoDolutegravir Sodium/Lamivudine64$193,786
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf33$159,640
JulucaDolutegravir/Rilpivirine31$150,583
TivicayDolutegravir Sodium47$148,737
RukobiaFostemsavir Tromethamine13$104,455
PifeltroDoravirine18$31,485
PrezcobixDarunavir/Cobicistat13$28,844
MounjaroTirzepatide25$26,472
OzempicSemaglutide17$19,454
IsentressRaltegravir Potassium11$15,117
IntelenceEtravirine11$11,324
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df26$6,366
Itraconazole12$3,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$3,570$513,054121 claims
MerckPifeltro, Isentress$29,688$46,60329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →